Asia Silicon Valley

Using Low-Dose X-Ray to Realize Tumor Cell-Targeted Radiotherapy for Treating Glioblastoma

Principal Investigator: Tse-Ying Liu, Prof. of National Yang-Ming University

Abstract

Glioblastoma (GBM, brain cancer) is the most malignant and invasive cancer, after making a definite diagnosis, the average survival period not more than 18 months. Our goal is to develop a radiation therapy to delay the recurrence of GBM. Our approach can concentrate the efficacy of radiation on GBM tumor cells, therefore, low dose of radiation is effective enough to kill GBM tumor cells, as much as possible to reduce the impact of radiation on normal cells. The core value of the program is that GBM patients can enjoy their life with quality over 2.5 years.

The features of product:

    • The impact on doctors and patients is very small.
    • No need to increase hospital investment.
    • Better efficacy with less cost.
1learn more
Team Introduction

Team Leader, Professor Tse-Ying Liu, received his Ph.D. in National Chiao-Tung University and was the Director of Process and Equipment R&D Department of Compeq Computer Co., Ltd., responsible for the development of new materials and new equipment employed for new product development. He is familiar with product development process and factory construction. During past few years, he also joined the biomedical product development project of some companies. Co-PI, Professor San-Yuan Chen, is a Chair Professor of National Chiao-Tung University. Since 2002, he had many excellent research results in the field of nano-biomaterials and repeatedly won the Ministry of Science and Technology Outstanding Award and National innovation award. Co-PI, Professor Ming-Hong Chen, was the head of the Department of Neurosurgery in NTU hospital (Hsinchu). He is now a neurosurgeon in Cathay Pacific Hospital. He received his Ph.D. in medical engineering, after which he is still actively involved in the development of medical devices and materials. They have been a common vision: through the combination of industry and academia, translate their research results into a clinical application.

Goals and Plan

To provide a novel medical device for prolonging the survival time of GBM patients.

Entry Barrier 

We are planning to propose a medical device that can enhance the therapeutic efficacy of chemotherapy, radiotherapy and chemoradiation therapy. Our product is an auxiliary rather than an alternative. Thus, market barriers and risks will be effectively reduced.

Market Scope

The global expenditure on chemotherapeutic agents for treating GBM is about USD 1.4 billion annually. We are planning to aim at the market of adjunct therapy after GBM resection, which is about USD 250 million per year. Currently, the revenue of the predicate is around 100 million per year. It is expected that the market size of the adjunct therapy increases with prolonging the life of patients. Hence, the revenue of our product will be gradually increased to 500 million while the significant therapeutic efficacy of the repeated use of our product is confirmed by the post market clinical follow-up.

Video Introduction